In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity

Participants with a baseline BMI of 35 or higher who took retatrutide 12 mg lost up to an average of 60.8 lbs (23.4%) of their body weight

Retatrutide reduced A1C by up to an average of 1.6%, with up to 40.0% reaching an A1C of 5.7%

INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and reductions in A1C.1 Results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, and simultaneously published in The Lancet.

"The vast majority of people with type 2 diabetes are also living with obesity, and treating the two together has always been a challenge," said Juan P. Frías, M.D., Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research. "In TRIUMPH-2, retatrutide reduced both weight and blood sugar substantially, with more than half of participants no longer qualifying as having obesity and up to 40% reaching an A1C in the normal range. Results such as these may change what we set out to achieve with a single therapy for adults living with type 2 diabetes and obesity."

Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively. Among participants with a baseline BMI of 35 or higher, those taking retatrutide 12 mg lost an average of 60.8 lbs (23.4%). By the end of the study, 59.5% of participants taking retatrutide 12 mg no longer met the BMI criteria for obesity.

Beyond substantially reducing weight, retatrutide also helped participants better control their A1C. Participants taking retatrutide 9 mg and 12 mg reduced their A1C by an average of 1.6% and 1.5%, respectively, while those taking 4 mg reduced their A1C by an average of 1.4%. Notably, up to 40.0% of participants reached an A1C of 5.7%, which is considered a normal blood sugar level.

Retatrutide also meaningfully reduced certain cardiovascular risk factors, with the highest dose delivering average reductions of 39.5% in triglycerides, 19.6% in non-HDL cholesterol, 10.8 mmHg in systolic blood pressure, 6.7 in (16.9 cm) in waist circumference, and 58.3% in high-sensitivity C-reactive protein (hsCRP).

"TRIUMPH-2 shows what the next generation of cardiometabolic medicine could deliver: substantial weight loss, A1C reduction and improvements across other critical cardiovascular risk factors," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "With efficacy this powerful and consistent across our Phase 3 program, we believe retatrutide could become an important option for people living with type 2 diabetes and obesity."

In TRIUMPH-2, the most common adverse events with retatrutide (4 mg, 9 mg, 12 mg vs. placebo, respectively) were diarrhea (27.4%, 33.5%, 33.6% vs. 13.2%), nausea (13.7%, 20.8%, 28.0% vs. 8.0%), constipation (14.0%, 16.2%, 16.8% vs. 9.4%), decreased appetite (5.8%, 12.3%, 17.1% vs. 4.5%), and vomiting (5.5%, 10.2%, 15.7% vs. 4.2%). Incidences of dysesthesia and urinary tract infections were 4.5%, 5.6%, 7.3% vs. 0.7% and 3.8%, 6.3%, 8.0% vs. 6.6% with retatrutide 4 mg, 9 mg, 12 mg vs. placebo, respectively. These events were generally mild to moderate, and the majority resolved during treatment. Discontinuation rates due to adverse events in TRIUMPH-2 were 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg) with retatrutide, compared with 4.9% for placebo.

Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 to the U.S. Food and Drug Administration. Additional results from the obstructive sleep apnea trial within TRIUMPH-2 will be presented at a future medical meeting and published in a peer-reviewed journal.

About retatrutide

Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.

About TRIUMPH-2 and the TRIUMPH clinical trial program

TRIUMPH-2 (NCT05929079) is a Phase 3, 80-week, randomized, double-blind and placebo-controlled trial under a basket design investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with type 2 diabetes and obesity or overweight. TRIUMPH-2 included a master trial for obesity and type 2 diabetes and a basket trial for moderate-to-severe obstructive sleep apnea. The study randomized 1,152 participants in a 1:1:1:1 ratio to receive retatrutide 4 mg, 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 4 mg (via a step at 2 mg), 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg). TRIUMPH-2 included a post-treatment follow-up period of 4 weeks.

The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, type 2 diabetes, moderate-to-severe obstructive sleep apnea (OSA) and obesity and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, has enrolled more than 5,800 participants with additional results anticipated over the next year.

Endnotes

- All data in this press release represent the efficacy estimand.

- The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) for 80 weeks without initiating prohibited weight management treatments (and glycemic rescue therapy for glycemic endpoints only).

U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS

Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

- Foundayo should not be used with other GLP-1 receptor agonist medicines.

- It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

- Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

- Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

- Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo.

NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Ares Management Corporation announced today that it will report earnings for the third quarter ending September 30, 2026 on Thursday, October 29, 2026 prior to the opening of the New York Stock Exchange. Ares Management Corporation will hold its webcast/conference call on the same day at 11:00 a.m. (Eastern Time) to discuss its third quarter ending September 30, 2026 financial results.

All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Home page of the Investor Resources section of our website at http://www.ares.com. Please visit the website to test your connection before the webcast. Domestic callers can access the conference call by dialing +1 (800) 267-6316. International callers can access the conference call by dialing +1 (203) 518-9783. All callers are asked to dial in 10-15 minutes prior to the call and to reference the conference ID ARESQ326 so that name and company information can be collected. For interested parties, an archived replay of the call will be available through November 29, 2026 to domestic callers by dialing +1 (800) 839-1192 and to international callers by dialing +1 (402) 220-0402. An archived replay will also be available through November 29, 2026 on a webcast link located on the Home page of the Investor Resources section of our website.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to advance our stakeholders' long-term goals by providing flexible capital that supports businesses and creates value for our investors and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of June 30, 2026, Ares Management Corporation's global platform had over $671 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit www.ares.com.

Investor Relations:

[email protected]

Media:

[email protected]

SOURCE Ares Management Corporation

Share this article

Dr. Aaron Asmus promoted to vice president of R&D; Lisa Selk named vice president of growth and innovation, R&D

AUSTIN, Minn., Sept. 29, 2026 /PRNewswire/ -- Hormel Foods Corporation (NYSE: HRL), a Fortune 500 global branded food company, today announced the promotion of Dr. Aaron Asmus to vice president of Research and Development (R&D).

Asmus will lead all functions within the company's R&D organization and report to Dr. Kevin Myers, senior vice president, R&D and food safety and quality.

"Aaron is an exceptional leader who combines deep technical expertise with a strong ability to build partnerships, develop talent and deliver results," said John Ghingo, president and chief executive officer-elect, Hormel Foods. "He has played an important role in strengthening our R&D capabilities, advancing key product and process initiatives, and fostering collaboration across the organization. His experience, leadership and track record of results make him well suited to lead this critical function."

In his new role, Asmus will oversee the company's R&D organization, helping drive innovation and commercialization across Hormel Foods while ensuring new products and technologies are developed with a continued focus on food safety, quality and regulatory excellence.

Hormel Foods is also strengthening its R&D organization with the addition of Lisa Selk as vice president, growth and innovation. Selk will report directly to Asmus and will be focused on growth, innovation, and the connection of R&D to consumers and the company's brands.

"Lisa's experience spans consumer insights, brand leadership and innovation, giving her a unique perspective on how we identify opportunities and bring new products to market," said Ghingo. "Her ability to connect consumer needs with business strategy will help strengthen our innovation pipeline and accelerate the commercialization of new products. Lisa is well prepared for this role and will be a strong addition to the R&D leadership team."

The appointments of Asmus and Selk are effective Oct. 26, 2026.

About Hormel Foods

Hormel Foods Corporation, based in Austin, Minnesota, is a global branded food company with over $12 billion in annual revenue. Its brands include PLANTERS®, SKIPPY®, SPAM®, HORMEL® NATURAL CHOICE®, APPLEGATE®, WHOLLY®, HORMEL® BLACK LABEL®, COLUMBUS®, JENNIE-O® and more than 30 other beloved brands. The Company is a member of the S&P 500 Index and the S&P 500 Dividend Aristocrats, was named one of the best companies to work for by U.S. News & World Report and one of America's most responsible companies by Newsweek, was recognized by TIME magazine as one of the World's Best Companies and has received numerous other awards and accolades for its corporate responsibility and community service efforts. For more information, visit hormelfoods.com.

SOURCE Hormel Foods Corporation

Share this article

Pressley Ridge Brings Together More Than 50 Professionals to Advance Kinship Care and Family-Centered Support in West Virginia

BRIDGEPORT, W. Va., Sept. 29, 2026 /PRNewswire/ -- Between September 15 and 18, the Bridgeport Conference Center served as the venue for the B~Hope Conference and Summit, an event hosted by Pressley Ridge that convened over 50 community partners, advocates, and child welfare experts from West Virginia.

The event furthered discussions regarding kinship support and family-centered care, specifically spotlighting the Family Centered Treatment Foundation® (FCT) model alongside the newly introduced Pressley Ridge B~Hope Embracing Kinship Caregivers curriculum. The session underscored the significance of providing caregivers and families with the necessary resources and instruments to succeed.

Pressley Ridge expresses its sincere gratitude to the West Virginia First Foundation for their sponsorship of this significant event. By fostering cooperation, creative approaches, and the exchange of knowledge, Pressley Ridge and its affiliates remain dedicated to fortifying family units, assisting kinship caregivers, and ensuring children maintain bonds with those most essential to their lives.

About Pressley Ridge

Pressley Ridge provides hope and support for youth, individuals and families through a full continuum of mental health, foster and kinship care, residential treatment, and specialized education services. Our innovative programs provide a safe and supportive environment where children, youth and families can work to increase their sense of wellbeing and achieve sustainable, positive outcomes.

SOURCE Pressley Ridge

Share this article

The article explains how recent sales, active competition, and buyer response can help sellers make informed pricing decisions as market conditions shift.

RIGBY, Idaho, Sept. 29, 2026 /PRNewswire/ -- How should sellers price their home when the market is changing?

HelloNation answers that question in an article featuring insights from Real Estate Expert Ted Whyte of Century 21 High Desert serving the Upper Snake River Valley, ID.

The article explains that an effective home pricing strategy considers more than a single estimate. Sellers can begin with recent comparable sales while also evaluating current competition and how buyers are responding to available properties.

Comparable sales provide evidence of what buyers recently paid for similar homes. The article notes that useful comparisons often share characteristics such as location, size, age, style, and features. In a changing real estate market, recent transactions may offer more relevant information than older sales.

Current competition adds another layer to the pricing decision. While past sales show completed transactions, competing listings reveal what buyers can choose from today. A property may appear reasonably priced based on previous transactions but still face stronger alternatives based on condition, features, or location.

The article explains that the asking price is a strategic decision rather than a guarantee of the final selling price. It can also affect which buyers discover the property because many buyers search within defined price ranges. An asking price significantly above similar options may reduce serious interest.

Market conditions can continue shifting after a property is listed. Inventory, mortgage rates, seasonal patterns, and buyer demand can change, making a flexible home pricing strategy useful. Sellers can establish expectations before listing and identify signs that may suggest the property's position should be reviewed.

Showing activity is one source of information. If competing listings are receiving buyer attention while one property attracts few showings, the article notes that price may deserve further consideration. Presentation, marketing, condition, and accessibility should also be examined before concluding that price is responsible.

Buyer feedback can provide additional context about how a home compares with other choices. Repeated observations about condition, features, or perceived value may reveal patterns that sellers can consider. The article cautions against placing too much importance on one comment, while consistent buyer feedback may provide useful information.

Offers also provide evidence about buyer perceptions. Several offers below the listed price may indicate a gap between seller expectations and what buyers perceive as value. However, financing, contingencies, timing, and other terms should be considered along with price when reviewing an offer.

The changing real estate market does not stop moving when a listing becomes active. New homes can enter the market, competing listings can change their prices, and additional sales can close. These developments may affect how buyers evaluate a property even when the home itself remains unchanged.

For that reason, the article recommends basing a price adjustment on evidence rather than guesswork. Sellers can review new sales, showing activity, changes in competition, and buyer responses. This approach allows pricing decisions to reflect current information instead of relying only on expectations established before listing.

The article concludes that pricing is an ongoing process when conditions are shifting. Recent market evidence provides a foundation, while active competition and buyer behavior offer new information after the property reaches the market. Reviewing those signals can help sellers adapt their decisions as conditions develop.

How Should I Price My Home in a Changing Market? features insights from Ted Whyte, Real Estate Expert of the Upper Snake River Valley, ID, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

Company purchases approximately 378,000 SF on 27 acres adjacent to Newport News/Williamsburg International Airport

NEWPORT NEWS, Va., Sept. 29, 2026 /PRNewswire/ -- An affiliate of Phoenix Investors ("Phoenix"), a national commercial real estate investment firm based in Milwaukee, Wisconsin, announced the acquisition of a 378,331-square-foot industrial property located at 615 Bland Boulevard in Newport News, Virginia. The facility sits on approximately 27.4 acres in a core, infill location within one of the most land-constrained industrial markets in the country, where large-block availability is limited.

Formerly operated by Continental's Vitesco Technologies division, the property is located adjacent to the Newport News/Williamsburg International Airport and approximately one mile from I-64 at the Jefferson Avenue interchange. The site is in close proximity to Fort Eustis, Langley Air Force Base, Yorktown Naval Weapons Station, and Camp Peary, placing it within one of the country's largest concentrations of defense, shipbuilding, and advanced manufacturing activity and providing tenants with access to a highly skilled labor force. The property is also located within a federal Opportunity Zone.

Originally constructed in 1971, the facility is well-suited for manufacturing users. The building is fully climate controlled throughout both the warehouse and office areas and features 16,000 amps of 277/480-volt three-phase electrical service, a wet fire suppression system, a 6-inch water main with separate fire and irrigation lines, and access to up to 12 million gallons of groundwater annually for cooling tower makeup. The site includes ten dock doors, three drive-in doors, 493 surface parking spaces, and a significant amount of excess land, providing capacity for expansion, outdoor storage, or additional trailer parking.

Phoenix plans to reposition the property through a series of capital improvements designed to make the building's configuration more conducive to modern manufacturers. Planned work will focus on reconfiguring the building's layout and loading areas, updating building systems, and enhancing the site to accommodate a broad range of manufacturing and light industrial users.

"Newport News is a dense, land-constrained market with very little large-block industrial availability, and 615 Bland Boulevard is a one-of-a-kind asset within it," said Anthony Crivello, President of Phoenix Investors. "The combination of heavy power, a fully climate-controlled environment, significant excess land, and a location adjacent to the airport makes this facility exceptionally well-suited for manufacturing. With the improvements we have planned, we expect to deliver a property that meets the needs of today's manufacturers, and we look forward to investing in the Newport News community and its skilled workforce."

The sale transaction was brokered by Grant Bates, Executive Managing Director of Newmark. Leasing inquiries may be directed to Luke Herder, VP of Acquisition & Leasing at Phoenix, at (414) 244-9575.

About Phoenix Investors

Phoenix Investors is the leading expert in the acquisition, renovation, and release of former manufacturing facilities in the United States. In addition to being one of the country's largest owners of industrial real estate, Phoenix has expanded its platform to include the acquisition and repositioning of data center assets, supporting the growing demand for digital infrastructure. The revitalization of facilities throughout the continental United States positively transforms communities and restarts the economic engine in the communities we serve. Phoenix's affiliate companies hold equity interests in a portfolio of industrial properties totaling approximately 88 million square feet and spanning 27 states, delivering corporations with a cost-effective national footprint to dynamically supply creative solutions to meet their leasing needs.

For more information, please visit https://phoenixinvestors.com.

SOURCE Phoenix Investors

Share this article

AGS American Glass Services, a portfolio company of The Sterling Group, Acquires Mark Industries

OSHKOSH, Wis., Sept. 29, 2026 /PRNewswire/ -- AGS American Glass Services ("AGS" or the "Company"), a portfolio company of The Sterling Group Foundation Fund ("Sterling"), has completed the acquisition of Mark Industries ("Mark"), a commercial glazing contractor based in Elgin, IL.

Mark Industries provides fabrication and installation of commercial glass systems for warehouse, office, retail, and other building types throughout the greater Chicago area. With in-house fabrication capabilities and a reputation for high-quality project execution, Mark brings a tenured glazier workforce and long-standing customer relationships in its local market. Josh Cunningham, Mark's owner and President, joined the AGS platform following closing and will continue to lead the business.

The acquisition extends AGS's footprint into the Chicago metropolitan market and places Mark in close proximity to AGS's East Moline operations, creating opportunities to better serve customers across northern Illinois.

Sterling launched AGS in July 2025 through its investment in Omni Glass & Paint and East Moline Glass, two long-standing Midwest glazing businesses that serve as the platform's core operating companies, with the goal of building a market-leading commercial glazing and coatings platform across the Midwest. Since then, AGS has invested in platform infrastructure and a suite of centralized services to support operations. With the addition of Mark, we believe AGS is one of the largest glazing contractors in the Midwest and ranks among the top glazing platforms in the United States by revenue. The Company continues to pursue acquisition opportunities in both existing and new markets.

About AGS American Glass Services

AGS American Glass Services, headquartered in Oshkosh, Wisconsin, is a leading provider of custom glass and coating solutions to customers across the Midwest and one of the largest commercial glazing companies in the United States. Launched in July 2025 with Omni Glass & Paint and East Moline Glass as its core operating businesses, AGS also includes Arrow Glass, Elite Glass & Metal, Cedar Rapids Glass Company, and Mark Industries. The Company provides commercial glass installation, paint and coating services, tempered glass distribution, and glass products for specialty vehicles, with in-house fabrication and coatings capabilities that support scalable growth. AGS now has approximately 500 employees across 10 locations and draws on more than 65 years of operating history. For more information, please visit www.agsglassgroup.com.

About The Sterling Group

Founded in 1982, The Sterling Group is a private equity and private credit investment firm that targets investments in basic manufacturing, distribution, and industrial services companies. Typical enterprise values of these companies at initial formation range from $100 million to $1 billion. Sterling has sponsored the buyout of 78 platform companies and numerous add-on acquisitions for a total transaction value of over $27 billion. Sterling currently has approximately $9 billion of assets under management. For further information, please visit www.sterling-group.com.

Past performance is no guarantee of future results and all investments are subject to loss. Represents Sterling's opinions, beliefs, and assessments. Although Sterling believes these assessments are reasonable, they are inherently subjective in nature.

SOURCE AGS American Glass Services

Share this article

385 Oil Refinery Workers in New Jersey Demand Fair Contract

LINDEN, N.J., Sept. 29, 2026 /PRNewswire/ -- Members of Teamsters Local 877 at Phillips 66 Bayway Refinery have voted by an overwhelming 92 percent margin to authorize a strike. The 385 process and mechanical workers work at the largest oil refinery on the East Coast.

The workers are demanding a contract that delivers higher wages, stronger benefits, reliable access to paid time off, and protects contractual language previously negotiated and agreed upon.

"If a strike occurs, it will be because Phillips 66 management has left these workers with no other choice," said Jeff Sanford, President of Local 877. "Our members are standing together for a fair contract that recognizes the essential work they perform every day at Bayway."

In 2025, management implemented an Absence Control Policy that allows discipline, up to and including termination, for employee absences due to illness.

Management has proposed changes that would compromise safety, including reducing qualification requirements and shortening the current 30-month training period for new employees. The company has also proposed tying probationary status to qualification milestones that could take up to six years to complete, replacing the current 10-month probationary period.

"These workers are in a demanding and essential industry. Without their labor, the Northeast's energy infrastructure would crumble," said Juan Campos, Director of the Teamsters Tankhaul Division. "If management thinks they can drag their feet and force workers to settle for less, they're in for a sobering wake up call. The Teamsters are united and we aren't backing down."

Negotiations are ongoing, but no agreement has been reached. The current collective bargaining agreement expires on Oct 1.

"We put our health, safety, and livelihoods on the line to keep this refinery running, and we expect to be compensated accordingly," said Fred Trachsler, an 18-year operator and Local 877 steward. "We're not going to accept weaker safety standards, blatant concessions, or policies that punish workers. If management keeps this up, we'll have to fight on the picket line."

The Phillips 66 Bayway Refinery processes 275 million barrels of crude oil and 145 million barrels of gasoline products each day. Last year, they generated $4.4 billion.

Founded in 1903, the International Brotherhood of Teamsters represents 1.3 million hardworking people in the U.S., Canada, and Puerto Rico. Visit Teamster.org for more information. Follow us on X @Teamsters and on Facebook at Facebook.com/teamsters.

Contact:

Lena Melentijevic, (347) 208-2279

[email protected]

SOURCE International Brotherhood of Teamsters

Share this article

AKRON, Ohio, Sept. 29, 2026 /PRNewswire/ -- The Board of Directors of FirstEnergy Corp. (NYSE: FE) today declared a quarterly dividend of 46.5 cents per share of outstanding common stock payable December 1, 2026, to shareholders of record at the close of business on November 6, 2026.

FirstEnergy is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation's largest investor-owned electric systems, serving more than 6 million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company's transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy online at www.firstenergycorp.com and on X @FirstEnergyCorp.

Forward-Looking Statements: This news release includes forward-looking statements based on information currently available to management and unless the context requires otherwise, references to "we," "us," "our" and "FirstEnergy" refers to FirstEnergy Corp. and its subsidiaries. Such statements are subject to certain risks and uncertainties and readers are cautioned not to place undue reliance on these forward-looking statements. These statements include declarations regarding management's intents, beliefs and current expectations. These statements typically contain, but are not limited to, the terms "anticipate," "potential," "expect," "forecast," "target," "will," "intend," "believe," "project," "estimate," "plan" and similar words. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, which may include the following: the potential liabilities, increased costs and unanticipated developments resulting from government investigations and agreements, including those associated with compliance with or failure to comply with the Deferred Prosecution Agreement entered into July 21, 2021 and settlements with the U.S. Attorney's Office for the Southern District of Ohio and the Securities and Exchange Commission ("SEC"); the risks and uncertainties associated with government investigations and audits regarding Ohio House Bill 6, as passed by Ohio's 133rd General Assembly ("HB 6") and related matters, including potential adverse impacts on federal or state regulatory matters, including, but not limited to, matters relating to rates; the risks and uncertainties associated with litigation, arbitration, mediation and similar proceedings, particularly regarding HB 6 related matters; changes in national and regional economic conditions, including recession, volatile interest rates, inflationary pressure, supply chain disruptions, higher fuel costs, and workforce impacts, affecting us and/or our customers and those vendors with which we do business; variations in weather, such as mild seasonal weather variations and severe weather conditions (including events caused, or exacerbated, by climate change, such as wildfires, hurricanes, flooding, droughts, high wind events and extreme heat events) and other natural disasters, which may result in increased storm restoration expenses or material liability and negatively affect future operating results; the potential liabilities and increased costs arising from regulatory actions or outcomes in response to severe weather conditions and other natural disasters; legislative and regulatory developments, and executive orders, including, but not limited to, matters related to rates, energy regulatory policies, compliance and enforcement activity, cyber security, climate change, and equity and inclusion; the ability to access the public securities and other capital and credit markets in accordance with our financial plans, the cost of such capital and overall condition of the capital and credit markets affecting us, including the increasing number of financial institutions evaluating the impact of climate change on their investment decisions, and the loss of FirstEnergy Corp.'s status as a well-known seasoned issuer; the risks associated with physical attacks, such as acts of war, terrorism, sabotage or other acts of violence, and cyber-attacks and other disruptions to our, or our vendors', information technology system, which may compromise our operations, and data security breaches of sensitive data, intellectual property and proprietary or personally identifiable information; the ability to accomplish or realize anticipated benefits through establishing a culture of continuous improvement and our other strategic and financial goals, including, but not limited to, executing Energize365, our transmission and distribution investment plan, executing on our rate filing strategy, controlling costs, improving credit metrics, maintaining investment grade ratings, strengthening our balance sheet and growing earnings; changing market conditions affecting the measurement of certain liabilities and the value of assets held in our pension trusts may negatively impact our forecasted growth rate, results of operations and may also cause it to make contributions to its pension sooner or in amounts that are larger than currently anticipated; changes in assumptions regarding factors such as economic conditions within our territories, the reliability of our transmission and distribution system, our generation resource planning in West Virginia, or the availability of capital or other resources supporting identified transmission and distribution investment opportunities; human capital management challenges, including among other things, attracting and retaining appropriately trained and qualified employees and labor disruptions by our unionized workforce; mitigating exposure for remedial activities associated with retired and formerly owned electric generation assets, including those sites impacted by the legacy coal combustion residual rules that were finalized during 2024, and the Environmental Protection Agency's reconsideration of such rule; changes to environmental laws and regulations, including, but not limited to, federal and state rules related to climate change, and potential changes to such laws and regulations; changes in customers' demand for power, including, but not limited to, economic conditions, the impact of climate change, emerging technology, particularly with respect to electrification, energy storage and distributed sources of generation; future actions taken by credit rating agencies that could negatively affect either our access to or terms of financing or our financial condition and liquidity; the potential of non-compliance with debt covenants in our credit facilities; the ability to comply with applicable reliability standards and energy efficiency and peak demand reduction mandates; changes to significant accounting policies; any changes in tax laws or regulations, including, but not limited to, the Inflation Reduction Act of 2022, the One Big Beautiful Bill Act of 2025, as signed into law on July 4, 2025, or adverse tax audit results or rulings and potential changes to such laws and regulations; the ability to meet our publicly-disclosed goals relating to climate-related matters, opportunities, improvements, and efficiencies, including FirstEnergy's Greenhouse gas reduction goals' and the risks and other factors discussed from time to time in FirstEnergy Corp.'s SEC filings. Dividends declared from time to time on FirstEnergy Corp.'s common stock during any period may in the aggregate vary from prior periods due to circumstances considered by the FirstEnergy Corp. Board at the time of the actual declarations. A security rating is not a recommendation to buy or hold securities and is subject to revision or withdrawal at any time by the assigning rating agency. Each rating should be evaluated independently of any other rating. These forward-looking statements are also qualified by, and should be read together with, the risk factors included in FirstEnergy Corp.'s Form 10-K, Form 10-Q and in other filings with the SEC. The foregoing review of factors also should not be construed as exhaustive. New factors emerge from time to time, and it is not possible for management to predict all such factors, nor assess the impact of any such factor on FirstEnergy Corp.'s business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statements. FirstEnergy Corp. expressly disclaims any obligation to update or revise, except as required by law, any forward-looking statements contained herein or in the information incorporated by reference as a result of new information, future events or otherwise.

SOURCE FirstEnergy Corp.

Share this article

PINE BLUFF, Ark., Sept. 29, 2026 /PRNewswire/ -- Simmons First National Corporation (NASDAQ: SFNC) today announced it is scheduled to release third quarter 2026 earnings after the market closing on Thursday, October 15, 2026. Management will conduct a live conference call to review this information beginning at 7:30 a.m. Central Time on Friday, October 16. Interested parties can listen to the call by dialing toll-free 1-844-481-2779 (North America only) and asking for the Simmons First National Corporation conference call, conference ID 10212015. In addition, the call will be available live or in recorded version on our website at simmonsbank.com under the "Investor Relations" tab. The recorded version will be available for at least 60 days following the date of the call.

Simmons First National Corporation

Simmons First National Corporation (NASDAQ: SFNC) is a Mid-South based financial holding company that has paid cash dividends to its shareholders for 117 consecutive years. Its principal subsidiary, Simmons Bank, operates 220 branches in Arkansas, Kansas, Missouri, Oklahoma, Tennessee and Texas. Founded in 1903, Simmons Bank offers comprehensive financial solutions delivered with a client-centric approach. Recently, Simmons Bank was recognized by Newsweek as one of America's Best Regional Banks and Credit Unions 2026 and by Forbes as one of America's Best-In-State Companies 2026. In 2025, Simmons Bank was recognized by Newsweek as one of America's Greatest Workplaces 2025 in Arkansas and one of America's Best Regional Banks 2025, and by U.S. News & World Report as one of the 2024-2025 Best Companies to Work For in the South. Additional information about Simmons Bank can be found on our website at simmonsbank.com, by following @Simmons_Bank on X or by visiting our newsroom.

SOURCE Simmons First National Corporation

Share this article